Long term efficacy and safety of ustekinumab in patients with moderate to severe psoriasis through 5 years of follow-up: results from the PHOENIX 1 long-term extension

被引：0
|
作者：
Papp, K. [1 ]
Kimball, A. [2 ,3 ]
Wasfi, Y. [4 ]
Chan, D.
Bissonnette, R. [5 ]
Sofen, H. [6 ]
Yeilding, N. [1 ]
Li, S. [4 ]
Szapary, P. [4 ]
Gordon, K. [7 ,8 ]
机构：
[1] Prob Med Res, Waterloo, ON, Canada
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Janssen Res & Dev LLC, Spring House, PA USA
[5] Innovaderm Res Inc, Montreal, PQ, Canada
[6] Dermatol Res Associates, Los Angeles, CA USA
[7] N Shore Univ Hlth Syst, Chicago, IL USA
[8] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
来源：
JOURNAL OF DERMATOLOGY | 2012年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：239 / 240
页数：2
相关论文
共 50 条
  • [1] Long-term efficacy and safety of ustekinumab in patients with moderate to severe psoriasis through 5 years of follow-up: results from the PHOENIX 1 long-term extension
    Kimball, A. B.
    Papp, K. A.
    Wasfi, Y.
    Chan, D.
    Bissonnette, R.
    Sofen, H.
    Yeilding, N.
    Li, S.
    Szapary, P. O.
    Gordon, K. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 : 63 - 64
  • [2] Long-term safety of ustekinumab in patients with moderate to severe psoriasis through up to 5 years of continuous follow-up
    Papp, Kim
    Reich, Kristian
    Lebwohl, Mark
    Szapary, Philippe
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB205 - AB205
  • [3] Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
    Papp, K. A.
    Griffiths, C. E. M.
    Gordon, K.
    Lebwohl, M.
    Szapary, P. O.
    Wasfi, Y.
    Chan, D.
    Hsu, M. -C.
    Ho, V.
    Ghislain, P. D.
    Strober, B.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (04) : 844 - 854
  • [4] Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up
    Langley, R. G.
    Lebwohl, M.
    Krueger, G. G.
    Szapary, P. O.
    Wasfi, Y.
    Chan, D.
    Hsu, M. C.
    You, Y.
    Poulin, Y.
    Korman, N.
    Prinz, J. C.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (05) : 1371 - 1383
  • [5] Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years
    Kimball, A. B.
    Gordon, K. B.
    Fakharzadeh, S.
    Yeilding, N.
    Szapary, P. O.
    Schenkel, B.
    Guzzo, C.
    Li, S.
    Papp, K. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (04) : 861 - 872
  • [6] Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
    Kimball, A. B.
    Papp, K. A.
    Wasfi, Y.
    Chan, D.
    Bissonnette, R.
    Sofen, H.
    Yeilding, N.
    Li, S.
    Szapary, P.
    Gordon, K. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (12) : 1535 - 1545
  • [7] Long-term efficacy of ustekinumab in moderate-to-severe psoriasis
    Kimball, A. B.
    Gordon, K. B.
    Fakharzadeh, S.
    Yeilding, N.
    Szapary, P. O.
    Schenkel, B.
    Guzzo, C.
    Li, S.
    Papp, K. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (04)
  • [8] Long-Term Safety Of Ustekinumab: 5 Years Of Follow-Up From The Psoriasis Clinical Development Program Including Patients With Psoriatic Arthritis
    Papp, Kim
    Griffiths, Christopher E. M.
    Gordon, Kenneth B.
    Lebwohl, Mark
    Szapary, Philippe O.
    Wasfi, Yasmine
    Chan, Daphne
    Shen, Yaung-Kaung
    Ho, Vincent
    Ghislain, Pierre-Dominique
    Strober, Bruce
    Reich, Kristian
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S139 - S140
  • [9] Long-term safety of ustekinumab: 5 years of follow-up from the psoriasis clinical development program including patients with psoriatic arthritis
    Papp, K.
    Griffiths, C. E. M.
    Gordon, K.
    Lebwohl, M.
    Szapary, P. O.
    Wasfi, Y.
    Chan, D.
    Shen, Y. K.
    Ho, V.
    Ghislain, P. D.
    Strober, B.
    Reich, K.
    SWISS MEDICAL WEEKLY, 2014, 144 : 5S - 5S
  • [10] Long-term safety of ustekinumab: 5 years of follow-up from the psoriasis clinical development program including patients with psoriatic arthritis
    Papp, Kim
    Reich, Kristian
    Lebwohl, Mark
    Wasfi, Yasmine
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB174 - AB174
12345